Biohaven (BHVN) Total Non-Current Liabilities (2021 - 2026)
Biohaven (BHVN) posted Total Non-Current Liabilities of $332.3 million for Q1 2026, down 15.82% sequentially from $394.8 million in Q4 2025, and up 199.06% YoY from $111.1 million in Q1 2025.
Analysis
Biohaven (BHVN) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Biohaven has reported Total Non-Current Liabilities for 6 years, with the latest figure at $332.3 million in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 199.06% year-over-year to $332.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $332.3 million (up 199.06% YoY) and the FY2025 annual result came in at $394.8 million, up 111.11% from the prior year.
- Total Non-Current Liabilities slipped to $332.3 million in Q1 2026 per BHVN's latest filing, from $394.8 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $394.8 million in Q4 2025 and troughed at $28.4 million in Q3 2022.
- A 5-year average of $161.6 million and a median of $143.8 million in 2023 frame the typical range for Total Non-Current Liabilities.
- The widest YoY moves for Total Non-Current Liabilities: up 218.14% in 2023, down 31.19% in 2023.
- Over 5 years, Total Non-Current Liabilities stood at $120.6 million in 2022, then sank by 31.19% to $83.0 million in 2023, then jumped by 125.33% to $187.0 million in 2024, then jumped by 111.11% to $394.8 million in 2025, then decreased by 15.82% to $332.3 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $332.3 million, $394.8 million, and $158.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Biohaven | 2.37 Bn | 2.10 Bn | - | 355.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 355.03 Mn |
| Mar 31, 2026 | 332.35 Mn |
| Dec 31, 2025 | 394.79 Mn |
| Sep 30, 2025 | 421.69 Mn |
| Jun 30, 2025 | 411.19 Mn |
| Mar 31, 2025 | 194.84 Mn |
| Dec 31, 2024 | 187.01 Mn |
| Sep 30, 2024 | 182.20 Mn |
| Jun 30, 2024 | 186.72 Mn |
| Mar 31, 2024 | 113.67 Mn |
| Dec 31, 2023 | 82.99 Mn |
| Sep 30, 2023 | 90.46 Mn |
| Jun 30, 2023 | 116.96 Mn |
| Mar 31, 2023 | 143.77 Mn |
| Dec 31, 2022 | 120.60 Mn |
| Sep 30, 2022 | 28.44 Mn |
| Dec 31, 2021 | 44.73 Mn |